Why is STAAR Surgical stock sliding today?
Investing.com -- STAAR Surgical stock fell 5.6% in pre-open trading after the company released preliminary second-quarter 2026 net sales the prior evening, reporting revenue expected to exceed $90 million — a figure that more than doubled the $44.3 million posted in the same period last year but landed essentially in-line with the Street consensus of approximately $90.2 million. The in-line result, rather than a meaningful beat, triggered a classic "sell the news" dynamic that sent shares down roughly 8.4% in after-hours trading before partially recovering into the pre-market session.
Reported by 2 outlets — Investing.com · Stock Market. See all sources ↓
Investing.com -- STAAR Surgical stock fell 5.6% in pre-open trading after the company released preliminary second-quarter 2026 net sales the prior evening, reporting revenue expected to exceed $90 million — a figure that more than doubled the $44.3 million posted in the same period last year but landed essentially in-line with the Street consensus of approximately $90.2 million. The in-line result, rather than a meaningful beat, triggered a classic "sell the news" dynamic that sent shares down roughly 8.4% in after-hours trading before partially recovering into the pre-market session. On the analyst front, Canaccord Genuity reiterated a Buy rating and $32 price target following the announcement, but tempered enthusiasm by indicating it would hold off on revising its estimates until the full Q2 results are reported on August 12, 2026. The firm specifically flagged the need for firmer footing on permanent management — the company has been operating under interim co-CEOs — and the reinstatement of formal financial guidance as prerequisites for greater conviction.
Read the full report at Investing.com · Stock Market ↗
Why it matters
2 outlets are covering this world story — one to watch as reporting develops.
- What's the story?
- Investing.com -- STAAR Surgical stock fell 5.6% in pre-open trading after the company released preliminary second-quarter 2026 net sales the prior evening, reporting revenue expected to exceed $90 million — a figure that more than doubled the $44.3 million posted in the same period last year but landed essentially in-line with the Street consensus of approximately $90.2 million. The in-line result, rather than a meaningful beat, triggered a classic "sell the news" dynamic that sent shares down roughly 8.4% in after-hours trading before partially recovering into the pre-market session.
- How widely is it covered?
- 2 outlets, average source rating 6.0/10.
- When was it last updated?
- 3m ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
Why is STAAR Surgical stock sliding today?
Sources1TypeCoverageInvesting.com · Stock Market